golnerminogene pradenovec
AXP000150.1 · Viral vector gene therapy
- Platform
- adenovirus (Ad5, E1-deleted, radiation-inducible EGR1 promoter)
- Targets
- TNF
- Originator
- GenVec
- Sponsor
- GenVec
Names
| Name | Type | Source |
|---|---|---|
| golnerminogene pradenovec | preferred name, INN | curator, ncit |
| TNFerade | brand | ncit |
| ADgv EGR.TNF.11D | code | ncit |
| Ad 5-TNF Alpha ambiguous | synonym | ncit |
Virus
- Role
- In vivo gene transfer
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5
- Replication
- non replicating
- Modifications
- E1-deleted adenoviral vector; human TNF-alpha under the radiation-inducible EGR1 promoter
- Transgenes
- TNF
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C26444
Approvals
No regulatory approval recorded.
Clinical trials (7)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT01048151 | TNFerade Biologic to Treat Locally Advanced Prostate Cancer | Unknown | Phase 1 | 20 | Locally Advanced Prostate Cancer | ||
| NCT00496535 | A Study of TNFerade™ Biologic With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck Cancer | Completed | Phase 1/2 | Head and Neck Cancer; Head and Neck Neoplasms | |||
| NCT00496236 | Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer | Completed | Phase 1/2 | Head and Neck Cancer; Head and Neck Neoplasms | |||
| NCT00261404 | TNFerade™ Biologic Plus Radiation for Metastatic Melanoma | Completed | Phase 2 | Melanoma | |||
| NCT00137878 | TNFerade™ Plus Chemo/Radiation/Surgery for Rectal Cancer | Completed | Phase 2 | Rectal Cancer | |||
| NCT00051480 | Study of TNFerade™ Gene Therapy, Radiation, 5-FU and Cisplatin in Esophageal Cancer | Completed | Phase 2 | Esophageal Cancer | |||
| NCT00051467 | A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer | Completed | Phase 3 | Pancreatic Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 23104721 | A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. | Annals of oncology : official journal of the European Society for Medical Oncology | 2013 | name in title: ADgv EGR.TNF.11D |
| PMID 23341531 | Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2013 | cited by trial NCT00051467 |
| PMID 22248601 | EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. | Gastrointestinal endoscopy | 2012 | name in title: TNFerade |
| PMID 22520270 | Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. | Gastrointestinal endoscopy | 2012 | cited by trial NCT00051480 |
| PMID 21447969 | A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer. | Oncology | 2010 | name in title: TNFerade |
| PMID 19734632 | Surgical resection after TNFerade therapy for locally advanced pancreatic cancer. | JOP : Journal of the pancreas | 2009 | name in title: TNFerade |
| PMID 18253139 | Endoscopic ultrasound delivery of an antitumor agent to treat a case of pancreatic cancer. | Nature clinical practice. Gastroenterology & hepatology | 2008 | name in abstract: TNFerade |
| PMID 17653822 | Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response. | Clinical & experimental metastasis | 2007 | name in abstract: TNFerade |
| PMID 16132372 | TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up. | Annals of surgical oncology | 2005 | name in title: TNFerade |
| PMID 14726502 | TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2004 | name in title: TNFerade |
| PMID 15355902 | A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2004 | name in title: TNFerade |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 26600634 | TNFerade, an innovative cancer immunotherapeutic. | Indian journal of pharmacology | 2015 | name in title: TNFerade |
| PMID 23852521 | Radiation oxygen biology with pulse electron paramagnetic resonance imaging in animal tumors. | Advances in experimental medicine and biology | 2013 | name in abstract: TNFerade |
| PMID 21222122 | The promise of a personalized genomic approach to pancreatic cancer and why targeted therapies have missed the mark. | World journal of surgery | 2011 | name in abstract: TNFerade |
| PMID 21880146 | Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression. | Molecular cancer | 2011 | name in abstract: TNFerade |
| PMID 21103287 | The society for gastrointestinal intervention. Are we, as an organization of disparate disciplines, cooperative or competitive? | Gut and liver | 2010 | name in abstract: TNFerade |
| PMID 18974777 | Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy. | Cancer gene therapy | 2009 | name in abstract: TNFerade |
| PMID 19444302 | Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers. | Cancer gene therapy | 2009 | name in title: TNFerade |
| PMID 19444305 | Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer. | Cancer gene therapy | 2009 | name in abstract: TNFerade |
| PMID 16082378 | Ionizing radiation: a genetic switch for cancer therapy. | Cancer gene therapy | 2006 | name in abstract: TNFerade |
| PMID 14726507 | TNFerade to the rescue? Guidelines for evaluating phase I cancer gene transfer trials. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2004 | name in title: TNFerade |
| PMID 14508100 | Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology. | Cancer biology & therapy | 2003 | name in abstract: TNFerade |
| PMID 14513689 | Technology evaluation: TNFerade, GenVec. | Current opinion in molecular therapeutics | 2003 | name in title: TNFerade |
| PMID 12386834 | TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. | Cancer gene therapy | 2002 | name in title: TNFerade |
| PMID 11399232 | Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors. | Human gene therapy | 2001 | name in title: TNFerade |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R01CA113662 | DNA Damage Targeted Gene Therapy in Head & Neck Cancer | UNIVERSITY OF CHICAGO | WEICHSELBAUM, RALPH R | 2005–2009 | name in abstract: TNFerade |
| R21CA115018 | KLH-pulsed dendritic cells plus TNFerade in Pancreatic Cancer | EAST CAROLINA UNIVERSITY | ZERVOS, EMMANUEL E | 2006–2007 | name in title: TNFerade |
| R43CA105733 | Activation of the Immune System by TNFerade | GENVEC, INC. | KING, C. RICHTER | 2004–2004 | name in title: TNFerade |
Notes
TNFerade: adenovirus carrying human TNF-alpha under the radiation-inducible EGR1 promoter, injected into the tumour and combined with radiotherapy. Reached a phase 3 trial in locally advanced pancreatic cancer (NCT00051467) with 5-fluorouracil and radiation, which did not improve survival. Construct name ADGVEGR.TNF.11D.
How to cite
golnerminogene pradenovec (AXP000150.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000150.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.